<DOC>
	<DOC>NCT02639078</DOC>
	<brief_summary>Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-0714 in healthy subjects.</brief_summary>
	<brief_title>Single Ascending Dose Study of TD-0714 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Body Mass Index (BMI) 18 to 32 kg/m2 inclusive Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective methods of birth control Women of nonchildbearing potential are at least 2 years postmenopausal or are surgically sterile Males must abstain from sex or use highly effective methods of birth control Negative for HIV, and Hepatitis A, B, and C Female subjects who are pregnant, lactating, breastfeeding or planning to become pregnant during the study. Subjects with a history of angioedema. Subject has evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. Subject has acute illness (gastrointestinal, infection [e.g., influenza] or known inflammatory process) Subject bradycardia Subject has hypertension Subjects has orthostatic hypotension Subjects has orthostatic tachycardia Subject has a known personal or family history of congenital long QT syndrome or known family history of sudden death. Subject has donated blood or blood components or has had blood loss exceeding 400 mL within the 90 days prior to Screening. Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Single ascending dose</keyword>
	<keyword>volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>first-in-human</keyword>
	<keyword>TD-0714</keyword>
</DOC>